Home>>Signaling Pathways>> Proteases>> Drug Metabolite>>Palifosfamide

Palifosfamide (Synonyms: Isophosphoramide Mustard, NSC 297900)

Catalog No.GC14762

An active metabolite of ifosfamide

Products are for research use only. Not for human use. We do not sell to patients.

Palifosfamide Chemical Structure

Cas No.: 31645-39-3

Size Price Stock Qty
5mg
$164.00
In stock
10mg
$239.00
In stock
50mg
$659.00
In stock
200mg
$1,599.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Protocol

Cell experiment:

Palifosfamide is dissolved in phosphate buffered saline (PBS). Cells are plated in 96-well microtiter plates with approximately 500 cells per well in 100 μL of media. After 24 h of incubation at 37°C, cells are treated with increasing concentrations of palifosfamide lysine in separate plates either as a single-day treatment or three consecutive days of treatment, with fresh drug being added each day. The plates are incubated for 72 h at 37°C with 5% CO2. After 72 h, 250 μg of MTT is added to each well and incubated at 37°C for 6 h. MTT is converted to formazine crystals by mitochondria of viable cells, which are then dissolved in 100 μL of dimethyl sulfoxide. Optical density is measured at 595 nm[2].

Animal experiment:

Mice: CB17 female SCID mice are used in the study. Once the tumors reached 50–150 mm3, mice are randomized into control and treatment groups (5-8 mice/group) for each tumor line. Cyclophosphamide is administered at the dose of 150 mg/kg intraperitoneally once a week for 6 weeks. Palifosfamide lysine is administered intravenously at the maximum tolerated dose of 100 mg/kg for three consecutive days as a one-time treatment and serial tumor volumes are determined over the next 6 weeks. Mice are sacrificed at the end of the experiment[2].

References:

[1]. Hingorani P, et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol. 2009 Sep;64(4):733-40.
[2]. Jones B, et al. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.

Background

Palifosfamide is the active moiety of ifosfamide (IFA) [1].
IFA is alkylating agents which are active against a variety of pediatric sarcomas such as rhabdomyosarcoma (RMS), Ewing's sarcoma (ES), osteosarcoma (OS) and other undifferentiated soft tissue sarcomas [1].
In human OS cell lines SaOS-2, OS229 and OS230, Palifosfamide lysine has broad activity with IC50 ranging from 2.25 to 6.75 μM. While OS222 had the IC50 of 31.5 μM [1].
In CB17 female SCID mice, palifosfamide lysine (100 mg/kg) administered intravenously for three consecutive days, the mean weight loss was less than 15% and complete recovery to baseline within 4 weeks of treatment. While, doses higher than 100 mg/kg for three consecutive days lead to either greater than 20% loss of body weight or death. In NCr-nu/nu mice bearing established orthotopic mammary MX-1 tumor xenografts, palifosfamide suppressed MX-1 tumor growth by greater than 80% with 17% complete antitumor responses [2].
References:
[1]. Hingorani P, Zhang W, Piperdi S, et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol, 2009, 64(4): 733-740.
[2]. Jones B, Komarnitsky P, Miller GT, et al. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs, 2012, 23(2): 173-184.

Chemical Properties

Cas No. 31645-39-3 SDF
Synonyms Isophosphoramide Mustard, NSC 297900
Chemical Name bis(2-chloroethylamino)phosphinic acid
Canonical SMILES C(CCl)NP(=O)(NCCCl)O
Formula C4H11Cl2N2O2P M.Wt 221.02
Solubility ≥ 22.1 mg/mL in DMSO, ≥ 19.4 mg/mL in Water with ultrasonic and warming Storage Store at -20°C, protect from light, stored under nitrogen
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 4.5245 mL 22.6224 mL 45.2448 mL
5 mM 0.9049 mL 4.5245 mL 9.049 mL
10 mM 0.4524 mL 2.2622 mL 4.5245 mL
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Reviews

Review for Palifosfamide

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Palifosfamide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.